PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Inhibitors of BCL-X L , combined with inhibition of the mTOR/4E-BP axis, drive regressions of PIK3CA mutant breast tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Proliferation, cell cycle and apoptosis in cancer
Evan, G. I., & Vousden, K. H. (2001) · Nature · doi:10.1038/35077213 · Cited by 2,724 · cited 1×
“Growth signaling and cell cycle pathways have been pharmacologically targeted with some success, but the effectiveness of these strategies has been limited by incomplete and transient therapeutic responses (2, 3).”
BackgroundMolecular mechanisms of mTOR-mediated translational control
Ma, X. M., & Blenis, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2672 · Cited by 2,558
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992 · cited 1×
“For the case of BCL-2/BCLXL inhibitors, these doses are 5- to 12-fold lower than the equivalent doses required to cause dose-limiting thrombocytopenia in human and large animal models, which are important considerations given the dose-limiting toxicities observed in human clinical trials with these and related agents…”
BackgroundTargeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Cited by
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 369
Fan, F., Liu, P., Bao, R., Chen, J., Zhou, M., Mo, Z., Ma, Y., Liu, H., Zhou, Y., Cai, X., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1547 · Cited by 198
“However, clinical experience has indicated that targeting a single oncoprotein is often not sufficient to achieve desired therapeutic efficacy due to the development of resistance either by functional redundancy of alternative pathways or genetic mutations that enable drug resistance in surviving cancer cells (9, 10).”
BackgroundMerino, D., Whittle, J. R., Vaillant, F., Serrano, A., Gong, J.-N., Giner, G., Maragno, A. L., Chanrion, M., Schneider, E., Pal, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7049 · Cited by 185
Protein translation: biological processes and therapeutic strategies for human diseases
Jia, X., He, X., Huang, C., Li, J., Dong, Z., & Liu, K. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01749-9 · Cited by 185
“134,135 Relatedly, in colorectal cancer, alterations in translation factors, including increased expression levels of eIFs, contribute to enhanced protein synthesis and upregulation of key factors involved in cell proliferation, tumor growth, metastasis, and oxaliplatin resistance.”
BackgroundDysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors
Anderson, G. R., Wardell, S. E., Çakır, M., Yip, C., Ahn, Y.-R., Ali, M., Yllanes, A. P., Chao, C., McDonnell, D. P., & Wood, K. C. (2018) · Nature Communications · doi:10.1038/s41467-018-04033-x · Cited by 146
Self-citationProtein synthesis control in cancer: selectivity and therapeutic targeting
Kovalski, J. R., Kuzuoğlu‐Öztürk, D., & Ruggero, D. (2022) · The EMBO Journal · doi:10.15252/embj.2021109823 · Cited by 130
Soderquist, R. S., Crawford, L. A., Liu, E., Lu, M., Agarwal, A., Anderson, G. R., Lin, K., Winter, P. S., Çakır, M., & Wood, K. C. (2018) · Nature Communications · doi:10.1038/s41467-018-05815-z · Cited by 138
Self-citationLindeman, G. J., Fernando, T. M., Bowen, R. L., Jerzak, K. J., Song, X., Decker, T. W., Boyle, F. M., McCune, S., Armstrong, A. C., Shannon, C., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3811 · Cited by 103
“Furthermore, PIK3CA-mutant breast cancer cell lines have been shown to exhibit increased dependence on BCLXL and MCL1, with dual inhibition resulting in strong antitumor activity (50).”
BackgroundKinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer
Donnella, H. J., Webber, J. T., Levin, R. S., Camarda, R., Momcilovic, O., Bayani, N., Shah, K. N., Korkola, J. E., Shokat, K. M., Goga, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0081-9 · Cited by 90
Arai, S., Jonas, O., Whitman, M. A., Corey, E., Balk, S. P., & Chen, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0549 · Cited by 74
“One prominent pathway for ERBB2 signaling is through ERBB3 phosphorylation and subsequent PI3K/AKTpathway activation, and previous studies indicate that PI3K activation can enhance MCL1 mRNA translation via mTORC1 (11, 20, 45).”
BackgroundAdapted to Survive: Targeting Cancer Cells with BH3 Mimetics
Montero, J., & Haq, R. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1334 · Cited by 86
“For instance, PIK3CAmutant breast cancer is sensitive to mTOR and BCLXL inhibition (153), estrogen receptor–positive (ER+) breast cancer to tamoxifen plus venetoclax (143), and HER2-amplified breast cancer to lapatinib with the MCL1 inhibitor S63845 (145).”
BackgroundJing, W., Guo, X., Wang, G., Bi, Y., Han, L., Zhu, Q., Qiu, C., Tanaka, M., & Zhao, Y. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106012 · Cited by 74
Song, K.-A., Hosono, Y., Turner, C., Jacob, S., Lochmann, T. L., Murakami, Y., Patel, N. U., Ham, J., Hu, B., Powell, K. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0304 · Cited by 73
“MCL-1 is functional in the response of EGFRi in EGFR-mutant NSCLCs MCL-1 is an experimentally proven drug target in several cancers (37–40) and is an important oncogene downstream of TORC1 (21, 25, 36, 41).”
BackgroundArai, S., Varkaris, A. S., Nouri, M., Chen, S., Xie, L., & Balk, S. P. (2020) · eLife · doi:10.7554/elife.54954 · Cited by 70
Zañudo, J. G. T., Scaltriti, M., & Albert, R. (2017) · Cancer Convergence · doi:10.1186/s41236-017-0007-6 · Cited by 64
“Several of these resistance mechanisms are supported by experimental evidence (Rb, MCL1, and BAD) or consistent with clinical observations (AKT) (46,47,49,53).”
Hoogenboezem, E. N., Patel, S. S., Lo, J. H., Cavnar, A. B., Babb, L. M., Francini, N., Gbur, E. F., Patil, P., Colazo, J. M., Michell, D. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45609-0 · Cited by 52
Lucantoni, F., Lindner, A. U., O’Donovan, N., Düßmann, H., & Prehn, J. H. M. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0039-y · Cited by 53
Zhu, Z., Liu, J., Yang, C., Zhao, M., & Xiong, Z. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1627-9 · Cited by 45
Khan, S., Kellish, P., Connis, N., Thummuri, D., Wiegand, J., Zhang, P., Zhang, X., Budamagunta, V., Hua, N., Yang, Y., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-022-01296-8 · Cited by 43
Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression
Kohli, J. S., Chen, G., Fitsiou, E., Doepner, M., Brandenburg, S. M., Faller, W. J., Ridky, T. W., & Demaria, M. (2022) · Nature Communications · doi:10.1038/s41467-022-35657-9 · Cited by 46
Yang, L., Ye, F., Bao, L., Zhou, X., Wang, Z., Hu, P., Ouyang, N., Li, X., Shi, Y., Chen, G., et al. (2019) · Cancer Science · doi:10.1111/cas.13976 · Cited by 42
Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer
Kitai, H., Choi, P. H., Yang, Y. C., Boyer, J. A., Whaley, A., Pancholi, P., Thant, C., Reiter, J., Chen, K., Markov, V., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50063-z · Cited by 41
MCL-1 is a clinically targetable vulnerability in breast cancer
Winder, M. L., & Campbell, K. J. (2022) · Cell Cycle · doi:10.1080/15384101.2022.2054096 · Cited by 38
“MCL-1 pro-survival functionality in the absence of genomic and transcriptomic MCL1 upregulation, indicating that targeting mTOR-mediated MCL-1 translation may provide an additional mechanism by which MCL-1 protein levels can be suppressed in some breast cancer subtypes (Figure 3) [71].”
BackgroundFooks, K., Galicia-Vázquez, G., Gife, V., Schcolnik‐Cabrera, A., Nouhi, Z., Poon, W. W. L., Luo, V. M., Rys, R. N., Aloyz, R. S., Orthwein, A., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02542-8 · Cited by 36
Signaling Pathways That Control Apoptosis in Prostate Cancer
Ali, A. A., & Kulik, G. (2021) · Cancers · doi:10.3390/cancers13050937 · Cited by 41
“The upregulation of MCL1 downstream of PI3K by transcriptional [180,181] and translational [182] mechanisms have been also reported.”
BackgroundER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins
Alcon, C., Zañudo, J. G. T., Albert, R., Wagle, N., Scaltriti, M., Letai, A. G., Samitier, J., & Montero, J. (2021) · Cells · doi:10.3390/cells10071659 · Cited by 33
“Notably, several laboratories have demonstrated the potential use of BH3 mimetics to improve HER2+ [33], PI3KCA mutant [34] and ER+ [35] breast cancer treatment.”
BackgroundShackleford, M. T., Rao, D. M., Bordeaux, E. K., Hicks, H. M., Towers, C. G., Sottnik, J. L., Oesterreich, S., & Sikora, M. J. (2020) · Cancers · doi:10.3390/cancers12102931 · Cited by 31
“In IDC cells, ER-driven mTOR activity increases MCL-1 levels [33] and mTOR inhibition reduces MCL-1 [42].”
BackgroundTargeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers
Fairlie, W. D., & Lee, E. F. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210750 · Cited by 28
Williams, M. M., Lee, L., Werfel, T. A., Joly, M. M., Hicks, D. J., Rahman, B., Elion, D. L., McKernan, C., Sanchez, V. M., Estrada, M. V., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0072-x · Cited by 30
Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers
Williams, M. M., Elion, D. L., Rahman, B., Hicks, D. J., Sanchez, V. M., & Cook, R. S. (2019) · Oncotarget · doi:10.18632/oncotarget.27070 · Cited by 29
“Importantly, Mcl-1 is a key survival factor used by several cancers to promote cell survival upon inhibition of Bcl-2 and BclxL, including ER+ breast cancers [17, 30].”
BackgroundResultInfluentialPrognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes
Elfgen, C., Reeve, K. A., Moskovszky, L. E., Güth, U., Bjelic‐Radisic, V., Fleisch, M. C., Tausch, C., & Varga, Z. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02968-2 · Cited by 26
Bonnefond, M.-L., Florent, R., Lenoir, S., Lambert, B., Abeilard, E., Giffard, F., Louis, M.-H., Elie, N., Briand, M., Vivien, D., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26084 · Cited by 24
Kim, S., Ahn, S. G., Mun, J.-Y., Jeong, M.-S., Bae, S. J., Lee, J., Jeong, J., Leem, S.-H., & Chu, I. (2020) · Cancers · doi:10.3390/cancers12020497 · Cited by 25
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer
Sarosiek, K. A., & Wood, K. C. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.10.004 · Cited by 25
Self-citationLi, S., & Li, X. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02315-1 · Cited by 17
Stanland, L. J., Ang, H. X., Hoj, J. P., Chu, Y., Tan, P. B. O., Wood, K. C., & Luftig, M. A. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0034 · Cited by 16
Self-citationWang, N., Mo, Z., Pan, L., Zhou, M., Ye, X., Liu, X., Cai, X., Qian, C., Chen, F., Xiong, Y., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-01006-z · Cited by 15
“Prior study has shown that MYC mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis [31].”
BackgroundKuzuoğlu‐Öztürk, D., Hu, Z., Rama, M., Devericks, E. N., Weiss, J., Chiang, G. G., Worland, S. T., Brenner, S. E., Goodarzi, H., Gilbert, L. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109321 · Cited by 16
“Importantly, the synthetic lethal interaction between eIF4E and Bcl-xL is in line with a previous study where the inhibition of Bcl-xL together with the mTOR pathway, which functions upstream of eIF4E, has been shown to induce apoptosis in PIK3CA mutant breast cancer cells (Anderson et al., 2016).”
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress
Varkaris, A. S., Wang, K., Nouri, M., Kozlova, N. V., Schmidt, D. R., Stavridi, A.-M., Arai, S., Ambrosio, N., Poluben, L., Jiménez‐Vacas, J. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60238-x · Cited by 14
Tada, M., Sumi, T., Tanaka, Y., Hirai, S., Yamaguchi, M., Miyajima, M., Niki, T., Takahashi, H., Watanabe, A., & Sakuma, Y. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.014 · Cited by 12
Pesch, A. M., Chandler, B. C., Michmerhuizen, A. R., Carter, H. M., Hirsh, N. H., Wilder-Romans, K., Liu, M., Ward, T., Ritter, C. L., Nino, C. A., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0024 · Cited by 12
“In addition, the synthetic vulnerability of PTEN loss and pharmacologic Mcl-1 inhibition has been explored in the context of PTEN -deficient models of glioblastoma (54), but our study is the first to demonstrate that both PIKCA mutations and PTEN loss in breast cancer cells can induce resistance to Bcl-xL inhibitor–m…”
InfluentialMolecular Features and Translational Outlook for Epstein–Barr virus-associated Gastric Cancer
Stanland, L. J., & Luftig, M. A. (2018) · Future Virology · doi:10.2217/fvl-2018-0071 · Cited by 9
Ji, Y., Harris, M. A., Newton, L. M., Harris, T. J., Fairlie, W. D., Lee, E. F., & Hawkins, C. J. (2024) · BMC Cancer · doi:10.1186/s12885-024-13088-7 · Cited by 8
Yao, J., Li, M., Jiang, Y., Yao, N., Liu, Y., Lv, L., Li, Y., Huang, J., Zha, J., & Xu, B. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02756-7 · Cited by 7
“…clinical evidence suggests that targeting a single oncoprotein often proves inadequate to achieve desired therapeutic outcomes due to functional redundancy in alternative pathways or acquired resistance mutations [28, 29], which ultimately enable tumor cell survival and therapeutic evasion.”
Therapeutic Enhancement of Verteporfin‐mediated Photodynamic Therapy by mTOR Inhibitors
Kraus, D., Palasuberniam, P., & Chen, B. (2019) · Photochemistry and Photobiology · doi:10.1111/php.13187 · Cited by 7
Zhang, X., Tao, Y., Xu, Z., Jiang, B., Yang, X., Huang, T., & Tan, W. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116542 · Cited by 7
Scott, S. C., Farago, A. F., Lai, W. V., ZAHURAK, M. L., Rudek, M. A., Murray, J., Carducci, M. A., Uziel, T., Takebe, N., Gore, S. D., et al. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04760-1 · Cited by 7
“Multiple other tumor types are predicted to respond to dual targeting of mTOR and BCL-2/xL including lymphoma, acute myeloid leukemia (AML), and molecular subsets of breast cancer and colorectal cancer supporting further development of this strategy [35–38].”
Shi, Y., Niu, P., Cheng, Q., Chen, L., Weng, Y., & Yang, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1631415 · Cited by 5
Manzella, G., Moonamale, D. C., Römmele, M., Bode, P. K., Wachtel, M., & Schäfer, B. W. (2021) · Neoplasia · doi:10.1016/j.neo.2021.07.001 · Cited by 4
Tiwari, S., Kaur, H., Anees, M., Gupta, P., Dalela, M., Kharbanda, S. M., & Singh, H. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122343 · Cited by 4
Arai, S., Chen, S., Xie, L., & Balk, S. P. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.12.903369 · Cited by 2
“Indeed, preclinical studies indicate that navitoclax may be 50 efficacious in solid tumors when used in combination with other agents acting through a variety 51 of mechanisms, including by decreasing MCL1 expression (11,16-22).”
BackgroundSensitivity and Resistance to BH3 Mimetics in Cancer Therapy
Floros, K. V., Faber, A. C., & Harada, H. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_7 · Cited by 1
Fooks, K., Galicia-Vázquez, G., Gife, V., Schcolnik‐Cabrera, A., Nouhi, Z., Poon, W. W. L., Luo, V. M., Rys, R. N., Aloyz, R. S., Orthwein, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22614635
Metadata
- Authors
- Anderson, G. R., Wardell, S. E., Cakir, M., Crawford, L., Leeds, J. C., Nussbaum, D. P., Shankar, P. S., Soderquist, R. S., Stein, E. M., Tingley, J. P., Winter, P. S., Zieser-Misenheimer, E. K., Alley, H. M., Yllanes, A., Haney, V., Blackwell, K. L., McCall, S. J., McDonnell, D. P., & Wood, K. C.
- Affiliations
- Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27710, USA.
- Duke University (US)
- Corresponding author
- Wood, Kris C.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-12-14
- Volume
- 8
- Issue
- 369
- Pages
- 369ra175-369ra175
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5626456
- OpenAlex
- W2563571637
- Cited by
- 53
- References
- 57
- Citations by year
- 2025: 4 · 2024: 5 · 2023: 4 · 2022: 10 · 2021: 7 · 2020: 4 · 2019: 7 · 2018: 10 · 2017: 2
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
- Funders
- Duke University School of Medicine
- Duke Cancer Institute
- NIH Building Interdisciplinary Research Careers in Women’s Health Program (K12HD043446)
- Golfers Against Cancer Research Award
- Stewart Trust Fellowship
- NSF (DGE-1106401, DGF-1106401)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- PIK3CA mutation, breast cancer, mTOR signaling, 4E-BP, Bcl-xL inhibitors, tumor dependency, combination therapy, PI3K/Akt signaling
- MeSH terms
- Animals, Breast Neoplasms, DNA Mutational Analysis, Female, Humans, Mice, Nude, Mutation, Neoplasm Transplantation, Gene Expression Regulation, Neoplastic, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Combinatorial Chemistry Techniques, MAP Kinase Signaling System, Cell Line, Tumor, bcl-X Protein, Mice, Class I Phosphatidylinositol 3-Kinases, TOR Serine-Threonine Kinases, Molecular Targeted Therapy, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.